ACRV
insider transactionsAcrivon Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 3 different insiders made open-market purchases in the last 365 days, totalling $114.3K.
Net shares · 365d
+67.8K
67.8K buy · 0 sell
Net value · 365d
$114.3K
$114.3K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
3
67.8K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·F
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$24.6K
13.7K sh · $1.79
Own -1%
-
Grant·A
Director, 10% Owner
$0
9.4K sh
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Grant·A
Chief Accounting Officer
$0
14.2K sh
Own +364%
-
Grant·A
Chief Medical Officer
$0
38.8K sh
Own New
-
Grant·A
Chief Legal Officer
$0
49.8K sh
Own +151%
-
Grant·A
Adam D. Levy KEY
Chief Financial Officer
$0
46.2K sh
Own +220%
-
Grant·A
Chief Development Officer
$0
38.6K sh
Own +268%
-
Grant·A
Chief Operating Officer
$0
73.0K sh
Own +99%
-
Grant·A
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$0
72.7K sh
Own +23%
-
Grant·A
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$0
180.1K sh
Own +9%
-
Other·F
Chief Accounting Officer
$190
99 sh · $1.92
Own -2%
-
Other·F
Chief Legal Officer
$353
184 sh · $1.92
Own -1%
-
Other·F
Chief Development Officer
$776
404 sh · $1.92
Own -3%
-
Other·F
Chief Operating Officer
$1.2K
613 sh · $1.92
Own -1%
-
Other·F
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$941
490 sh · $1.92
Own -0%
-
Other·F
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$2.4K
1.3K sh · $1.92
Own -0%
-
Grant·A
Director, 10% Owner
$7.0M
3.9M sh · $1.80
Own +49%
-
Other·F
Chief Legal Officer
$993
558 sh · $1.78
Own -2%
-
Grant·A
Chief Accounting Officer
$0
31.9K sh
Own New
-
Grant·A
Chief Medical Officer
$0
174.1K sh
Own New
-
Grant·A
Chief Legal Officer
$0
129.8K sh
Own New
-
Grant·A
Adam D. Levy KEY
Chief Financial Officer
$0
132.9K sh
Own New
-
Grant·A
Chief Development Officer
$0
94.9K sh
Own New
-
Grant·A
Chief Operating Officer
$0
186.7K sh
Own New
-
Grant·A
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$0
185.5K sh
Own New
-
Grant·A
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$0
417.2K sh
Own New
-
Other·F
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$21.8K
14.3K sh · $1.53
Own -1%
-
Other·F
Chief Accounting Officer
$189
116 sh · $1.63
Own -3%
-
Other·F
Chief Legal Officer
$354
217 sh · $1.63
Own -1%
-
Other·F
Chief Development Officer
$768
471 sh · $1.63
Own -3%
-
Other·F
Chief Operating Officer
$1.2K
723 sh · $1.63
Own -1%
-
Other·F
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$944
579 sh · $1.63
Own -0%
-
Other·F
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$2.1K
1.3K sh · $1.63
Own -0%
-
Other·F
Chief Legal Officer
$1.3K
659 sh · $1.98
Own -2%
-
Buy·P
Peter Blume-Jensen / Kristina Masson KEY
President and CEO
$82.1K
49.0K sh · $1.68
Own +2%
-
Buy·P
Adam D. Levy KEY
Chief Financial Officer
$15.0K
8.8K sh · $1.70
Own +73%
-
Buy·P
Chief Operating Officer
$17.2K
10.0K sh · $1.72
Own +15%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 21, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Other F | 13.7K | $24.6K |
| May 18, 2026 | RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah | Grant A | 9.4K | $0 |
| May 18, 2026 | Michael John Tomsicek | Grant A | 9.4K | $0 |
| May 18, 2026 | Sharon Shacham | Grant A | 9.4K | $0 |
| May 18, 2026 | Santhosh Palani | Grant A | 9.4K | $0 |
| May 18, 2026 | Ivana Magovcevic-Liebisch | Grant A | 9.4K | $0 |
| May 18, 2026 | Derek Dirocco | Grant A | 9.4K | $0 |
| May 18, 2026 | Charles M Baum | Grant A | 9.4K | $0 |
| May 18, 2026 | Katharine Peterson | Grant A | 14.2K | $0 |
| May 18, 2026 | Mansoor Raza Mirza | Grant A | 38.8K | $0 |
| May 18, 2026 | Mary Miller | Grant A | 49.8K | $0 |
| May 18, 2026 | Adam D. Levy KEY | Grant A | 46.2K | $0 |
| May 18, 2026 | Erick Gamelin | Grant A | 38.6K | $0 |
| May 18, 2026 | Eric Devroe | Grant A | 73.0K | $0 |
| May 18, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Grant A | 72.7K | $0 |
| May 18, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Grant A | 180.1K | $0 |
| May 14, 2026 | Katharine Peterson | Other F | 99 | $190 |
| May 14, 2026 | Mary Miller | Other F | 184 | $353 |
| May 14, 2026 | Erick Gamelin | Other F | 404 | $776 |
| May 14, 2026 | Eric Devroe | Other F | 613 | $1.2K |
| May 14, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Other F | 490 | $941 |
| May 14, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Other F | 1.3K | $2.4K |
| Apr 22, 2026 | RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah | Grant A | 3.9M | $7.0M |
| Apr 17, 2026 | Mary Miller | Other F | 558 | $993 |
| Mar 1, 2026 | Katharine Peterson | Grant A | 31.9K | $0 |
| Mar 1, 2026 | Mansoor Raza Mirza | Grant A | 174.1K | $0 |
| Mar 1, 2026 | Mary Miller | Grant A | 129.8K | $0 |
| Mar 1, 2026 | Adam D. Levy KEY | Grant A | 132.9K | $0 |
| Mar 1, 2026 | Erick Gamelin | Grant A | 94.9K | $0 |
| Mar 1, 2026 | Eric Devroe | Grant A | 186.7K | $0 |
| Mar 1, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Grant A | 185.5K | $0 |
| Mar 1, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Grant A | 417.2K | $0 |
| Feb 21, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Other F | 14.3K | $21.8K |
| Feb 14, 2026 | Katharine Peterson | Other F | 116 | $189 |
| Feb 14, 2026 | Mary Miller | Other F | 217 | $354 |
| Feb 14, 2026 | Erick Gamelin | Other F | 471 | $768 |
| Feb 14, 2026 | Eric Devroe | Other F | 723 | $1.2K |
| Feb 14, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Other F | 579 | $944 |
| Feb 14, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Other F | 1.3K | $2.1K |
| Jan 17, 2026 | Mary Miller | Other F | 659 | $1.3K |
| Jan 14, 2026 | Peter Blume-Jensen / Kristina Masson KEY | Buy P | 49.0K | $82.1K |
| Jan 14, 2026 | Adam D. Levy KEY | Buy P | 8.8K | $15.0K |
| Jan 13, 2026 | Eric Devroe | Buy P | 10.0K | $17.2K |
About ACRV insider trading
This page tracks insider transactions for Acrivon Therapeutics, Inc. (ACRV) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.